{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:36:47Z","timestamp":1791895007713,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12020-017-1306-5","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T06:17:36Z","timestamp":1493705856000},"page":"568-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Epidemiology, management and outcomes of Graves\u2019 disease\u2014real life data"],"prefix":"10.1007","volume":"56","author":[{"given":"Y. S.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Hookham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Allahabadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-2843","authenticated-orcid":false,"given":"S. P.","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,6]]},"reference":[{"issue":"3","key":"1306_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/2042018811408488","volume":"2","author":"CM Girgis","year":"2011","unstructured":"C.M. Girgis, B.L. Champion, J.R. Wall, Current concepts in graves\u2019 disease. Ther. Adv. Endocrinol. Metab. 2(3), 135\u2013144 (2011). doi:\n                        10.1177\/2042018811408488","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"9821","key":"1306_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/s0140-6736(11)60782-4","volume":"379","author":"JA Franklyn","year":"2012","unstructured":"J.A. Franklyn, K. Boelaert, Thyrotoxicosis. Lancet 379(9821), 1155\u20131166 (2012). doi:\n                        10.1016\/s0140-6736(11)60782-4","journal-title":"Lancet"},{"issue":"1","key":"1306_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/bmb\/ldr030","volume":"99","author":"MPJ Vanderpump","year":"2011","unstructured":"M.P.J. Vanderpump, The epidemiology of thyroid disease. Br. Med. Bull. 99(1), 39\u201351 (2011). doi:\n                        10.1093\/bmb\/ldr030","journal-title":"Br. Med. Bull."},{"key":"1306_CR4","doi-asserted-by":"crossref","unstructured":"Y. Shoenfeld, R. Cervera, M.E. Gershwin, Diagnostic criteria in Autoimmune diseases. 1st edn. Humana Press (2008)","DOI":"10.1007\/978-1-60327-285-8"},{"issue":"5","key":"1306_CR5","first-page":"575","volume":"168","author":"J Ginsberg","year":"2003","unstructured":"J. Ginsberg, Diagnosis and management of Graves\u2019 disease. Can. Med. Assoc. J. 168(5), 575\u2013585 (2003)","journal-title":"Can. Med. Assoc. J."},{"issue":"4-5","key":"1306_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","volume":"13","author":"F Menconi","year":"2014","unstructured":"F. Menconi, C. Marcocci, M. Marino, Diagnosis and classification of Graves\u2019 disease. Autoimmun. Rev. 13(4-5), 398\u2013402 (2014). doi:\n                        10.1016\/j.autrev.2014.01.013","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"1306_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cen.12688","volume":"84","author":"L Bartalena","year":"2016","unstructured":"L. Bartalena, H.B. Burch, K.D. Burman, G.J. Kahaly, A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease. Clin. Endocrinol. (Oxf). 84(1), 115\u2013120 (2016). doi:\n                        10.1111\/cen.12688","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"23","key":"1306_CR8","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2015.16535","volume":"314","author":"HB Burch","year":"2015","unstructured":"H.B. Burch, D.S. Cooper, Management of Graves disease a review. -J. Am. Med. Assoc. 314(23), 2544\u20132554 (2015). doi:\n                        10.1001\/jama.2015.16535","journal-title":"-J. Am. Med. Assoc."},{"issue":"6","key":"1306_CR9","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1210\/jc.2009-0850","volume":"94","author":"DS Cooper","year":"2009","unstructured":"D.S. Cooper, S.A. Rivkees, Putting propylthiouracil in perspective. J. Clin. Endocr. Metab. 94(6), 1881\u20131882 (2009). doi:\n                        10.1210\/jc.2009-0850","journal-title":"J. Clin. Endocr. Metab."},{"issue":"9","key":"1306_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"D.S. Cooper, Drug therapy: antithyroid 7drugs. New Engl. J. Med. 352(9), 905\u2013917 (2005). doi:\n                        10.1056\/NEJMra042972","journal-title":"New Engl. J. Med."},{"key":"1306_CR11","doi-asserted-by":"publisher","unstructured":"P. Abraham, A. Avenell, S.C. McGeoch, L.F. Clark, J.S. Bevan, Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst. Rev. 1, (2010). \n                        10.1002\/14651858.CD003420.pub4","DOI":"10.1002\/14651858.CD003420.pub4"},{"issue":"12","key":"1306_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1089\/thy.2015.0195","volume":"25","author":"D Villagelin","year":"2015","unstructured":"D. Villagelin, J.H. Romaldini, R.B. Santos, A.B.B.P. Milkos, L.S. Ward, Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12), 1282\u20131290 (2015). doi:\n                        10.1089\/thy.2015.0195","journal-title":"Thyroid"},{"issue":"4","key":"1306_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","volume":"49","author":"G Benker","year":"1998","unstructured":"G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, H. Hirche, European multicenter trial Grp treatment, H.: is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. Clin. Endocrinol. (Oxf). 49(4), 451\u2013457 (1998). doi:\n                        10.1046\/j.1365-2265.1998.00554.x","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"2","key":"1306_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2265.1989.tb01244.x","volume":"31","author":"AJ Hedley","year":"1989","unstructured":"A.J. Hedley, R.E. Young, S.J. Jones, W.D. Alexander, P.D. Bewsher, Antithyroid drugs in the treatment of hyperthyroidism of Graves-disease\u2013long-term follow-up of 434 patients. Clin. Endocrinol. (Oxf). 31(2), 209\u2013218 (1989). doi:\n                        10.1111\/j.1365-2265.1989.tb01244.x","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"1306_CR15","first-page":"1","volume":"0","author":"J Hookham","year":"2016","unstructured":"J. Hookham, E.E. Collins, A. Allahabadia, S.P. Balasubramanian, Variation in the use of definitive treatment options in the management of Graves\u2019 disease: a UK clinician survey. Postgrad. Med. J. 0, 1\u20137 (2016)","journal-title":"Postgrad. Med. J."},{"key":"1306_CR16","unstructured":"Office for National Statistics (OMIS). Advanced query for ONS of Sheffield postcodes with age or gender stratification. [15\/06\/14 12:15] Available from: \n                        https:\/\/www.nomisweb.co.uk\/"},{"issue":"5","key":"1306_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2265.2008.03338.x","volume":"69","author":"A McGrogan","year":"2008","unstructured":"A. McGrogan, H.E. Seaman, J.W. Wright, C.S. de Vries, The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin. Endocrinol. (Oxf). 69(5), 687\u2013696 (2008). doi:\n                        10.1111\/j.1365-2265.2008.03338.x","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"3","key":"1306_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1568-9972(03)00006-5","volume":"2","author":"GS Cooper","year":"2003","unstructured":"G.S. Cooper, B.C. Stroehla, The epidemiology of autoimmune diseases. Autoimmun. Rev. 2(3), 119\u2013125 (2003). doi:\n                        10.1016\/s1568-9972(03)00006-5","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"1306_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"HF Nystrom","year":"2013","unstructured":"H.F. Nystrom, S. Jansson, G. Berg, Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin. Endocrinol. (Oxf). 78(5), 768\u2013776 (2013). doi:\n                        10.1111\/cen.12060","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"1","key":"1306_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beem.2009.08.013","volume":"24","author":"P Laurberg","year":"2010","unstructured":"P. Laurberg, C. Cerqueira, L. Ovesen, L.B. Rasmussen, H. Perrild, S. Andersen, I.B. Pedersen, A. Carle, Iodine intake as a determinant of thyroid disorders in populations. Best Pract. Res. Clin. Endocrinol. Metab. 24(1), 13\u201327 (2010). doi:\n                        10.1016\/j.beem.2009.08.013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"10","key":"1306_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.autrev.2010.05.021","volume":"9","author":"K Zoephel","year":"2010","unstructured":"K. Zoephel, D. Roggenbuck, M. Schott, Clinical review about TRAb assay\u2019s history. Autoimmun. Rev. 9(10), 695\u2013700 (2010). doi:\n                        10.1016\/j.autrev.2010.05.021","journal-title":"Autoimmun. Rev."},{"key":"1306_CR22","unstructured":"B.T. Association UK Guidelines for the use of thyroid function tests. (2006)"},{"issue":"4","key":"1306_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000085736","volume":"14","author":"A Alnaqdy","year":"2005","unstructured":"A. Alnaqdy, M. Al-Maskari, Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves\u2019 disease. Med. Prin. Pract. 14(4), 209\u2013212 (2005). doi:\n                        10.1159\/000085736","journal-title":"Med. Prin. Pract."},{"issue":"4","key":"1306_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/cen.12478","volume":"81","author":"B Vaidya","year":"2014","unstructured":"B. Vaidya, A. Wright, J. Shuttleworth, M. Donohoe, R. Warren, A. Brooke, C.A. Gericke, O.C. Ukoumunne, Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves\u2019 disease: a retrospective observational study. Clin. Endocrinol. (Oxf). 81(4), 610\u2013613 (2014). doi:\n                        10.1111\/cen.12478","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"9","key":"1306_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1089\/thy.2010.1654","volume":"20","author":"K Boelaert","year":"2010","unstructured":"K. Boelaert, Treatment of Graves\u2019 disease with antithyroid drugs: current perspectives. Thyroid 20(9), 943\u2013946 (2010). doi:\n                        10.1089\/thy.2010.1654","journal-title":"Thyroid"},{"issue":"6","key":"1306_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/eje.1.02169","volume":"154","author":"S Razvi","year":"2006","unstructured":"S. Razvi, B. Vaidya, P. Perros, S.H.S. Pearce, What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves\u2019 disease. Eur. J. Endocrinol. 154(6), 783\u2013786 (2006). doi:\n                        10.1530\/eje.1.02169","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1306_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/eje.0.1470583","volume":"147","author":"BG Nedrebo","year":"2002","unstructured":"B.G. Nedrebo, P.I. Holm, S. Uhlving, J.I. Sorheim, S. Skeie, G.E. Eide, E.S. Husebye, E.A. Lien, S. Aanderud, Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease. Eur. J. Endocrinol. 147(5), 583\u2013589 (2002). doi:\n                        10.1530\/eje.0.1470583","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1306_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1046\/j.1365-2265.1998.00446.x","volume":"48","author":"SKG Grebe","year":"1998","unstructured":"S.K.G. Grebe, C.M. Feek, H.C. Ford, A randomized trial of short-term treatment of Graves\u2019 disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin. Endocrinol. (Oxf). 48(5), 585\u2013592 (1998). doi:\n                        10.1046\/j.1365-2265.1998.00446.x","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"9-10","key":"1306_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1515\/jpem-2012-0138","volume":"25","author":"H Sato","year":"2012","unstructured":"H. Sato, N. Sasaki, K. Minamitani, M. Minagawa, I. Kazukawa, S. Sugihara, K. Wataki, S. Konda, H. Inomata, K. Sanayama, Y. Kohno, Higher dose of methimazole causes frequent adverse effects in the management of Graves\u2019 disease in children and adolescents. J. Pediatr. Endocr. Met. 25(9-10), 863\u2013867 (2012). doi:\n                        10.1515\/jpem-2012-0138","journal-title":"J. Pediatr. Endocr. Met."},{"issue":"6","key":"1306_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/thy.2008.0364","volume":"19","author":"K Takata","year":"2009","unstructured":"K. Takata, S. Kubota, S. Fukata, T. Kudo, E. Nishihara, M. Ito, N. Amino, A. Miyauchi, Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19(6), 559\u2013563 (2009). doi:\n                        10.1089\/thy.2008.0364","journal-title":"Thyroid"},{"issue":"3","key":"1306_CR31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-57-3-563","volume":"57","author":"JH Romaldini","year":"1983","unstructured":"J.H. Romaldini, N. Bromberg, R.S. Werner, L.M. Tanaka, H.F. Rodrigues, M.C. Werner, C.S. Farah, L.C.F. Reis, Comparison of effects of high and low dosage regimens of anti-thyroid drugs in the management of graves hyperthyroidism. J. Clin. Endocr. Metab. 57(3), 563\u2013570 (1983)","journal-title":"J. Clin. Endocr. Metab."},{"issue":"1","key":"1306_CR32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1210\/jcem-58-1-62","volume":"58","author":"KW Wenzel","year":"1984","unstructured":"K.W. Wenzel, J.R. Lente, Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves-disease-evidence against an immunosuppressive action of thionamide drugs. J. Clin. Endocr. Metab. 58(1), 62\u201369 (1984)","journal-title":"J. Clin. Endocr. Metab."},{"issue":"2","key":"1306_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-2004-814217","volume":"36","author":"M Schott","year":"2004","unstructured":"M. Schott, N.G. Morgenthaler, R. Fritzen, J. Feldkamp, H.S. Willenberg, W.A. Scherbaum, J. Seissler, Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves\u2019 disease. Horm. Metab. Res. 36(2), 92\u201396 (2004). doi:\n                        10.1055\/s-2004-814217","journal-title":"Horm. Metab. Res."},{"issue":"3","key":"1306_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, R. Rocchi, E. Martino, A. Pinchera, Clinical features of patients with Graves\u2019 disease undergoing remission lifter antithyroid drug treatment. Thyroid 7(3), 369\u2013375 (1997). doi:\n                        10.1089\/thy.1997.7.369","journal-title":"Thyroid"},{"issue":"10","key":"1306_CR35","first-page":"427","volume":"49","author":"D Dauksiene","year":"2013","unstructured":"D. Dauksiene, A. Dauksa, N. Mickuviene, Independent pretreatment predictors of Graves\u2019 disease outcome. Medicina-(Kaunas) 49(10), 427\u2013434 (2013)","journal-title":"Medicina-(Kaunas)"},{"issue":"12","key":"1306_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/105072502321085225","volume":"12","author":"R Hoermann","year":"2002","unstructured":"R. Hoermann, B. Quadbeck, U. Roggenbuck, I. Szabolcs, J. Pfeilschifter, W. Meng, K. Reschke, K. Hackenberg, J. Dettmann, B. Prehn, H. Hirche, K. Mann, G. Basedow Study, Relapse of Graves\u2019 disease after successful outcome of antithyroid drug therapy: Results of a prospective randomized study on the use of levothyroxine. Thyroid 12(12), 1119\u20131128 (2002). doi:\n                        10.1089\/105072502321085225","journal-title":"Thyroid"},{"issue":"5","key":"1306_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/eje.0.1440475","volume":"144","author":"D Glinoer","year":"2001","unstructured":"D. Glinoer, P. de Nayer, M. Bex, Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves\u2019 hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. 144(5), 475\u2013483 (2001). doi:\n                        10.1530\/eje.0.1440475","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1306_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1507\/endocrj.K06-069","volume":"54","author":"C Cappelli","year":"2007","unstructured":"C. Cappelli, E. Gandossi, M. Castellano, C. Pizzocaro, B. Agosti, A. Delbarba, I. Pirola, E. De Martino, E.A. Rosei, Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120 months prospective study. Endocr. J. 54(5), 713\u2013720 (2007). doi:\n                        10.1507\/endocrj.K06-069","journal-title":"Endocr. J."},{"issue":"1","key":"1306_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12020-014-0289-8","volume":"48","author":"R Vita","year":"2015","unstructured":"R. Vita, D. Lapa, F. Trimarchi, S. Benvenga, Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves\u2019 disease. Endocrine 48(1), 254\u2013263 (2015). doi:\n                        10.1007\/s12020-014-0289-8","journal-title":"Endocrine"},{"issue":"9","key":"1306_CR40","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","volume":"15","author":"B Quadbeck","year":"2005","unstructured":"B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, G. Basedow Study, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves\u2019 disease. Thyroid 15(9), 1047\u20131054 (2005). doi:\n                        10.1089\/thy.2005.15.1047","journal-title":"Thyroid"},{"issue":"7","key":"1306_CR41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/BF03344157","volume":"29","author":"B Tarantini","year":"2006","unstructured":"B. Tarantini, C. Ciuoli, G. Di Cairano, E. Guarino, P. Mazzucato, A. Montanaro, L. Burroni, A.G. Vattimo, F. Pacini, Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoirnmune and non-autoimmune hyperthyroidism. J. Endocrinol. Invest. 29(7), 594\u2013598 (2006)","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"1306_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5603\/ep.2015.0019","volume":"66","author":"P Szumowski","year":"2015","unstructured":"P. Szumowski, S. Abdelrazek, A.K. Sawicka, M. Mojsak, J. Kostecki, M. Sykala, J. Mysliwiec, Radioiodine therapy for Graves\u2019 disease-retrospective analysis of efficacy factors. Endokrynol. Pol. 66(2), 126\u2013131 (2015). doi:\n                        10.5603\/ep.2015.0019","journal-title":"Endokrynol. Pol."},{"issue":"4","key":"1306_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/bjs.8660","volume":"99","author":"M Barczynski","year":"2012","unstructured":"M. Barczynski, A. Konturek, A. Hubalewska-Dydejczyk, F. Golkowski, W. Nowak, Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves\u2019 disease with a 5-year follow-up. Brit. J. Surg. 99(4), 515\u2013522 (2012). doi:\n                        10.1002\/bjs.8660","journal-title":"Brit. J. Surg."},{"issue":"3","key":"1306_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/hed.21175","volume":"32","author":"HM Mehanna","year":"2010","unstructured":"H.M. Mehanna, A. Jain, H. Randeva, J. Watkinson, A. Shaha, Postoperative hypocalcemia\u2013the difference a definition makes. Head Neck 32(3), 279\u2013283 (2010). doi:\n                        10.1002\/hed.21175","journal-title":"Head Neck"},{"issue":"9","key":"1306_CR45","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1590\/0004-2730000003569","volume":"58","author":"AA Tam","year":"2014","unstructured":"A.A. Tam, C. Kaya, F. Balkan, M. Kilic, R. Ersoy, B. Cakir, Thyroid nodules and thyroid cancer in Graves\u2019 disease. Arq. Bras. Endocrinol. Metabol. 58(9), 933\u2013938 (2014). doi:\n                        10.1590\/0004-2730000003569","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"issue":"1","key":"1306_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00268-013-2287-z","volume":"38","author":"M Ren","year":"2014","unstructured":"M. Ren, M.C. Wu, C.Z. Shang, X.Y. Wang, J.L. Zhang, H. Cheng, M.T. Xu, L. Yan, Predictive factors of thyroid cancer in patients with Graves\u2019 disease. World J. Surg. 38(1), 80\u201387 (2014). doi:\n                        10.1007\/s00268-013-2287-z","journal-title":"World J. Surg."},{"issue":"1","key":"1306_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12022-014-9343-6","volume":"26","author":"SZ Wei","year":"2015","unstructured":"S.Z. Wei, Z.W. Baloch, V.A. LiVolsi, Thyroid carcinoma in patients with Graves\u2019 disease: an institutional experience. Endocr. Pathol. 26(1), 48\u201353 (2015). doi:\n                        10.1007\/s12022-014-9343-6","journal-title":"Endocr. Pathol."},{"issue":"6","key":"1306_CR48","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ijom.2015.02.007","volume":"44","author":"P Stathopoulos","year":"2015","unstructured":"P. Stathopoulos, S. Gangidi, G. Kotrotsos, D. Cunliffe, Graves\u2019 disease: a review of surgical indications, management, and complications in a cohort of 59 patients. Int. J. Oral. Maxillofac. Surg. 44(6), 713\u2013717 (2015). doi:\n                        10.1016\/j.ijom.2015.02.007","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"issue":"3","key":"1306_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1308\/003588414x13814021679753","volume":"96","author":"O Edafe","year":"2014","unstructured":"O. Edafe, P. Prasad, B.J. Harrison, S.P. Balasubramanian, Incidence and predictors of post-thyroidectomy hypocalcaemia in a tertiary endocrine surgical unit. Ann. R. Coll. Surg. Engl. 96(3), 219\u2013223 (2014). doi:\n                        10.1308\/003588414x13814021679753","journal-title":"Ann. R. Coll. Surg. Engl."},{"issue":"4","key":"1306_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/bjs.8660","volume":"99","author":"M Barczynski","year":"2012","unstructured":"M. Barczynski, A. Konturek, A. Hubalewska-Dydejczyk, F. Golkowski, W. Nowak, Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves\u2019 disease with a 5-year follow-up. Br. J. Surg. 99(4), 515\u2013522 (2012). doi:\n                        10.1002\/bjs.8660","journal-title":"Br. J. Surg."},{"issue":"4","key":"1306_CR51","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jamcollsurg.2010.12.036","volume":"212","author":"DV Feliciano","year":"2011","unstructured":"D.V. Feliciano, J.D. Lyons, Thyroidectomy is optimal treatment for Graves\u2019 disease. J. Am. Coll. Surg. 212(4), 714\u2013720 (2011). doi:\n                        10.1016\/j.jamcollsurg.2010.12.036","journal-title":"J. Am. Coll. Surg."},{"issue":"478","key":"1306_CR52","first-page":"359","volume":"52","author":"E Henderson","year":"2002","unstructured":"E. Henderson, A. Berlin, J. Fuller, Attitude of medical students towards general practice and general practitioners. Brit. J. Gen. Pract. 52(478), 359\u2013363 (2002)","journal-title":"Brit. J. Gen. Pract."},{"issue":"2","key":"1306_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jamcollsurg.2009.03.025","volume":"209","author":"H In","year":"2009","unstructured":"H. In, E.N. Pearce, A.K. Wong, J.F. Burgess, D.B. McAneny, J.E. Rosen, Treatment options for Graves disease: a cost-effectiveness analysis. J. Am. Coll. Surg. 209(2), 170\u2013179 (2009). doi:\n                        10.1016\/j.jamcollsurg.2009.03.025","journal-title":"J. Am. Coll. Surg."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1306-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T05:45:48Z","timestamp":1494999948000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1306-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1306-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,6]]}}}